Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 434 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Alcohol linked to more than 740,000 new cancer cases globally in... July 14, 2021 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma August 14, 2025 Medicare Advantage Plans: Read the Fine Print November 16, 2020 Load more HOT NEWS Why Have Thyroid Cancer Diagnoses Spiked for US Women? The long road to targeting the holy grail of the immune... FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions Daughter Donates Hair to Mother After She Was Diagnosed with Stage...
